Renal cell carcinoma (RCC) remains one of the most lethal forms of urological cancer, despite advances in diagnosis and treatment over the past two decades.
The year 2024 began with a significant international discovery in the field of kidney cancer: the use of adjuvant therapy in patients with aggressive forms of kidney cancer extends their survival.
However, how do we distinguish patients who could benefit from it from those who might instead experience the side effects of the therapy without experiencing its benefits?
The European Association of Urology (EAU) recommends the use of precise prognostic models to identify those patients at high risk of disease recurrence for whom the administration of adjuvant therapy would control the disease for a longer period and extend their survival, according to the latest data.
However, the accuracy of these prognostic models varies considerably, and only some of them are truly useful in correctly classifying these patients.
Our work, therefore, has enabled the identification of the most accurate prognostic models to be applied based on the characteristics of the tumor, so as to correctly classify patients and optimize the selection of candidates for adjuvant therapy, identifying those who would truly benefit from it.
Giuseppe Rosiello1, Alessandro Larcher1, Giuseppe Fallara1, Cristina Giancristoforo1, Alberto Martini1, Chiara Re1, Francesco Cei1, Giacomo Musso1, Zhe Tian2, Pierre I. Karakiewicz2, Alexandre Mottrie 3,4, Roberto Bertini1, Andrea Salonia1, Andrea Necchi1, Daniele Raggi1, Alberto Briganti1, Francesco Montorsi1, Umberto Capitanio11 Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy.
2 Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
3 Department of Urology, Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium.
4 ORSI Academy, Melle, Belgium.
